Published in Blood on September 20, 2010
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Analysing and interpreting DNA methylation data. Nat Rev Genet (2012) 3.77
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood (2014) 1.64
A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell (2014) 1.27
Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J Biol Chem (2012) 1.23
Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol (2011) 1.18
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood (2013) 1.08
Method to detect differentially methylated loci with case-control designs using Illumina arrays. Genet Epidemiol (2011) 1.07
EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood (2012) 1.01
Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia (2013) 1.00
High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia. PLoS One (2012) 0.99
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. Oncologist (2014) 0.94
The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA. PLoS One (2011) 0.94
A noncanonical Flt3ITD/NF-κB signaling pathway represses DAPK1 in acute myeloid leukemia. Clin Cancer Res (2011) 0.88
Reproducibility and concordance of differential DNA methylation and gene expression in cancer. PLoS One (2012) 0.87
Evi1 forms a bridge between the epigenetic machinery and signaling pathways. Oncotarget (2011) 0.84
Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. Haematologica (2014) 0.83
Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer. Mol Carcinog (2011) 0.83
Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia. Cancers (Basel) (2013) 0.80
Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient. Front Pharmacol (2013) 0.78
Association between DNA methyltransferases 3B gene polymorphisms and the susceptibility to acute myeloid leukemia in Chinese Han population. PLoS One (2013) 0.77
Phosphorylation of the leukemic oncoprotein EVI1 on serine 196 modulates DNA binding, transcriptional repression and transforming ability. PLoS One (2013) 0.76
Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia. Epigenetics (2015) 0.76
Epigenetics in Cancer: A Hematological Perspective. PLoS Genet (2016) 0.75
Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: a case report. Biomark Res (2016) 0.75
EV(I1)olution of AML DNA methylation. Blood (2011) 0.75
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79
The epigenomics of cancer. Cell (2007) 30.91
The UCSC Genome Browser Database: 2008 update. Nucleic Acids Res (2007) 23.13
Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet (2007) 20.22
The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet (2009) 18.90
Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med (2004) 11.61
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A (2005) 8.10
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science (2002) 6.05
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med (2010) 4.76
A universal framework for regulatory element discovery across all genomes and data types. Mol Cell (2007) 4.50
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res (1996) 3.50
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood (2008) 2.86
MADE4: an R package for multivariate analysis of gene expression data. Bioinformatics (2005) 2.66
CG dinucleotide clustering is a species-specific property of the genome. Nucleic Acids Res (2007) 2.48
Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. Mol Cell Biol (1991) 1.77
An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One (2008) 1.76
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood (2009) 1.75
Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res (2005) 1.69
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol (2010) 1.64
DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun (2007) 1.53
A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a. FEBS Lett (2008) 1.38
Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol (1993) 1.30
Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat Clin Pract Oncol (2005) 1.29
BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer (2008) 1.20
Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol (2007) 1.07
TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins. J Proteome Res (2007) 1.02
Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies. Cancer Sci (2009) 1.00
The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase. Br J Haematol (2001) 0.95
The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells. Oncogene (2002) 0.94
Myeloid transforming protein Evi1 interacts with methyl-CpG binding domain protein 3 and inhibits in vitro histone deacetylation by Mbd3/Mi-2/NuRD. Biochemistry (2008) 0.93
A cross-linker-sensitive myeloid leukemia cell line from a 2-year-old boy with severe Fanconi anemia and biallelic FANCD1/BRCA2 mutations. Genes Chromosomes Cancer (2005) 0.93
Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption. Genes Chromosomes Cancer (2007) 0.86
The Evi-1 zinc finger myeloid transforming protein binds to genomic fragments containing (GATA)n sequences. Oncogene (1995) 0.81
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med (2004) 11.61
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol (2010) 9.24
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res (2006) 5.99
A molecular roadmap of reprogramming somatic cells into iPS cells. Cell (2012) 4.41
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
Therapeutic advances in acute myeloid leukemia. J Clin Oncol (2011) 3.69
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood (2008) 3.50
Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol (2008) 3.47
methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol (2012) 3.44
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33
Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol (2005) 3.15
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med (2004) 3.10
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica (2008) 3.06
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell (2010) 3.05
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet (2012) 2.94
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol (2007) 2.90
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood (2008) 2.86
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood (2008) 2.85
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 2.83
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood (2007) 2.77
Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol (2009) 2.70
Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood (2012) 2.56
Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev (2004) 2.56
PDZBase: a protein-protein interaction database for PDZ-domains. Bioinformatics (2004) 2.55
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood (2012) 2.55
CG dinucleotide clustering is a species-specific property of the genome. Nucleic Acids Res (2007) 2.48
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood (2010) 2.40
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A (2009) 2.35
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33
Quantitative information management for the biochemical computation of cellular networks. Sci STKE (2004) 2.32
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med (2009) 2.27
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol (2013) 2.22
Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell (2003) 2.20
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell (2012) 2.18
Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol Genomics (2007) 2.15
Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet (2006) 2.10
Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res (2007) 2.08
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer (2005) 2.08